ProS1

ProS1

ProS1 Molekülinformation

Molecule Name
Prostate-specific antigen
Molekülalias
PROS, PS21, PS22, PS23, PS24, PS25, PSA, THPH5, THPH6
Drug Development Progress
Anzahl der klinischen Arzneimittel2
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
P-30 antigen,Semenogelase,APS,Prostate-specific antigen,PSA,Kallikrein Related Peptidase 3,Gamma-Seminoprotein,Kallikrein-3,Seminin,Kallikrein 3, (Prostate Specific Antigen),EC 3.4.21.77,KLK2A1,HK3,KLK3,EC 3.4.21,EC:3.4.21.77
Molekülhintergrund
This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

ProS1 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Tb161-RAD402Tb161-RAD402Phase 2 ClinicalRadiopharm Theranostics Ltd
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
GEA-408GEA-408Phase 2 ClinicalGenEros Biopharma Hangzhou Ltd
Prostatic Neoplasms
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
AfalaApprovedMateria Medica Holding Research And Production CompanyRussian FederationProstatic Neoplasms; ProstatitisMateria Medica Holding Research And Production Company2014-01-01
Prostatic Neoplasms; Prostatitis
Details